Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma

References

• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445(7130):851–857. doi:https://doi.org/10.1038/nature05661.
   PubMed Web of Science ®Google Scholar
• Reed KB, Brewer JD, Lohse CM, Bringe KE, Pruit CN, Gibson LE. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clinic Proc. 2012;87:328–334.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2014 [Internet]. Atlanta: American Cancer Society Inc.; 2013 [ cited 2014 Oct 23]. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, et al. SEER cancer statistics review, 1975-2009 (Vintage 2009 Populations) [Internet]. Bethesda (MD): National Cancer Institute; April 2012 [cited 2014 Oct 23]. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/.
   Google Scholar
• Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, et al. SEER cancer statistics review, 1975-2004 [Internet]. Bethesda (MD): National Cancer Institute; 2007 [cited 2014 Oct 24]. Available from: http://seer.cancer.gov/csr/1975_2004.
   Google Scholar
• Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40:1825–1836.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–365.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Hodi FS. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist. 2013;18:717–725.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;(2013(10):588–598. doi:https://doi.org/10.1038/nrclinonc.2013.153.
   Google Scholar
• Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998;228:307–319.
   PubMed Web of Science ®Google Scholar
• McDermott D, Haanen J, Tt C, Lorigan P, O’Day S. Investigators MDX. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013;24:2694–2698.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. In J Clin Oncol. 2015; Feb 9. [Epub ahead of print]
   Google Scholar
• Hodi FS, Sznol M, Kluger HM, McDermott DF, Carvajal RD, Lawrence DP, Topalian SL, Atkins MB, Powderly JD, Sharfman WH, et al.Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial,J Clin Oncol:32, abstract,9002.2014.
   Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015a;372:320–330.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015b;372:2521–2532.
   PubMed Web of Science ®Google Scholar
• Js W, Sp D, Minor D, Fs H, Gutzmer R, Neyns B, Hoeller C, Ni K, Wh M, Cd L, et al. Nivolumab compared with chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 therapy. Lancet Oncol. 2015;16:375–384.
   PubMed Web of Science ®Google Scholar
• Fs H, Sj O, Df M, Rw W, Ja S, Jb H, Gonzalez R, Robert C, Schadendorf D, Jc H, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Jf B, Testori A, Jj G, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev Cancer. 2012;2:252–264.
   Web of Science ®Google Scholar
• Keytruda (pembrolizumab) prescribing information [Internet] Whitehouse Station (NJ): Merck & Co., Inc; 2014 [cited 2014 Oct 23]. 12p. Available from: http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
   Google Scholar
• Opdivo (nivolumab) prescribing information [Internet]. Princeton (NJ): Bristol-Myers Squibb Company; 2015 [ cited 2015 Jan 27]. 8p. Available from: http://packageinserts.bms.com/pi/pi_opdivo.pdf.
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Melanoma. Version 3, 2015. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed Jul 7
   Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–1570.
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–271.
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012;72:3125–3130.
   PubMed Web of Science ®Google Scholar
• Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193:1007–1008.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–1492.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889–897.
   Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116.
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–190.
   PubMed Web of Science ®Google Scholar
• Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453–479.
   PubMed Web of Science ®Google Scholar
• Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24:1169–1177.
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–499.
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–182.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Atkins MBPD-1. as a potential target in cancer therapy. Cancer Med. 2013;2:662–673.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008;224:141–165.
   PubMed Web of Science ®Google Scholar
• Fong L, Ej S. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275–5283.
   PubMed Web of Science ®Google Scholar
• Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297–339.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–477.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe A. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015–3029.
   PubMed Web of Science ®Google Scholar
• Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846–856.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Tolcher AW, Rasco DW, Papadopoulos KP, Beeram M, Drengler R, Chen C, Smith L, Perez C, et al.Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors,J Clin Oncol:31, abstract,2512.2012.
   Google Scholar
• Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6:S11–4.
   PubMed Web of Science ®Google Scholar
• Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008;14:5610–5618.
   PubMed Web of Science ®Google Scholar
• Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol. 2000;18:1954–1959.
   PubMed Web of Science ®Google Scholar
• Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33:1191–1196.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.
   PubMed Web of Science ®Google Scholar
• Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 2008;8:1.
   PubMedGoogle Scholar
• Yervoy (ipilimumab) prescribing information. Princeton (NJ): Bristol-Myers Squibb Company; 2013 [cited 2014 Apr 16]. Available from: http://packageinserts.bms.com/pi/pi_yervoy.pdf.
   Google Scholar
• Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu W-J, Gangadhar TC, et al. 2014. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 384(9948):1109–1117.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030.
   PubMed Web of Science ®Google Scholar
• Konrad MW, Hemstreet G, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE, Bradley EC. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 1990;50:2009–2017.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Kefford R, Hamid O, Daud A, Wolchok JD, Hwu W-J, Gangadhar TC, Patnaik A, Joshua AM, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol 2014; 32: abstractLBA9000.
   Google Scholar
• Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127–3132.
   PubMed Web of Science ®Google Scholar
• Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83:797–805.
   PubMed Web of Science ®Google Scholar
• Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol. 1995;18:272–278.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother. 2001;24:287–293.
   PubMed Web of Science ®Google Scholar
• Fisher B, Keenan AM, Garra BS, Steinberg SM, White DE, DiBisceglie AM, Hoofnagle JH, Yolles P, Rosenberg SA, Lotze MT. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol. 1989;7:1852–1862.
   PubMed Web of Science ®Google Scholar
• Guleria AS, Yang JC, Topalian SL, Weber JS, Parkinson DR, MacFarlane MP, White RL, Steinberg SM, White DE, Einhorn JH, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol. 1994;12:2714–2722.
   PubMed Web of Science ®Google Scholar
• Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1987;107:293–300.
   PubMed Web of Science ®Google Scholar
• Lee SH, Baig M, Rusciano V, Dutcher JP. Novel management of pruritus in patients treated with IL-2 for metastatic renal cell carcinoma and malignant melanoma. J Immunother. 2010;33:1010–1013.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
   PubMed Web of Science ®Google Scholar
• Bryce J, Passoni C. Nursing management of patients with metastatic melanoma receiving ipilimumab. Oncol Nurs Forum. 2013;40:215–218.
   PubMed Web of Science ®Google Scholar
• Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther. 2014;7:203–209.
   PubMed Web of Science ®Google Scholar
• Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013;18:733–743.
   PubMed Web of Science ®Google Scholar
• Ledezma B, Heng A. Real-world impact of education: treating patients with ipilimumab in a community practice setting. Cancer Manag Res. 2013;6:5–14.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–2697.
   PubMed Web of Science ®Google Scholar
• Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS, Investigators MDX. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119:1675–1682.
   PubMed Web of Science ®Google Scholar
• Squibb B-M. Yervoy (ipilimumab): immune-mediated adverse reaction management guide [Internet]. Princeton (NJ): Bristol-Myers Squibb; 2011 [cited 2014 Jun]. 18 p. Available from: https://www.hcp.yervoy.com/pdf/rems-management-guide.pdf.
   Google Scholar
• Merck. A guide to monitoring patients during treatment with Keytuda(pembrolizumab). Merck Sharp & Dohme Corp 2014. Available from: https://www.keytruda.com/static/pdf/adverse-reaction-management-tool.pdf.
   Google Scholar
• Squibb B-M. Opdivo (nivolumab) immune-mediated adverse reactions management guide. Princeton NJ: Bristol-Myers Squibb; 2015. Available from: http://www.opdivohcp.bmscustomerconnect.com/servlet/servlet.FileDownload?file=00Pi000000GL6RoEAL.
   Google Scholar
• Merrill SP, Reynolds P, Kalra A, Biehl J, Vandivier RW, Mueller SW. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother. 2014;48:806–810.
   PubMed Web of Science ®Google Scholar
• Slangen RM, van Den Eertwegh AJ, van Bodegraven AA, de Boer N. Diarrhoea in a patient with metastatic melanoma: ipilimumab ileocolitis treated with infliximab. World J Gastrointest Pharmacol Ther. 2013;4:80–82.
   PubMedGoogle Scholar
• Pagès C, Gornet JM, Monsel G, Allez M, Bertheau P, Bagot M, Lebbé C, Viguier M. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23:227–230.
   PubMed Web of Science ®Google Scholar
• Mavropoulos JC, Wang TS. Managing the skin toxicities from new melanoma drugs. Curr Treat Options Oncol. 2014;15:281–301.
   PubMed Web of Science ®Google Scholar
• Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13:278–280.
   PubMedGoogle Scholar
• Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014;16:589–593.
   PubMed Web of Science ®Google Scholar
• Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371–381.
   PubMed Web of Science ®Google Scholar
• Lammert A, Schneider HJ, Bergmann T, Benck U, Krämer BK, Gärtner R, Metzner C, Schöfl C, Berking C. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes. 2013;121:581–587.
   PubMed Web of Science ®Google Scholar
• Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015; Apr 17. [ Epub ahead of print.
   Web of Science ®Google Scholar
• Smith FO, Goff SL, Klapper JA, Levy C, Allen T, Mavroukakis SA, Rosenberg SA. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother. 2007;30:130.
   PubMed Web of Science ®Google Scholar
• Kaufman H, Lutzky J, Clark J, Margolin KA, Lawson DH, Amin A, Collichio FA, Pecora A, Urba WA, Bennett KL, et al. 2013. Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020. J Clin Oncol. 31(abstract):9050.
   Google Scholar
• Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681–6688.
   PubMed Web of Science ®Google Scholar
• Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, et al. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother. 2012;35:711–715.
   PubMed Web of Science ®Google Scholar
• Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013;24:2911–2915.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013;119:3687–3695.
   PubMed Web of Science ®Google Scholar
• Deo M, Van Maanen A, Cornélis F, De Potter P, Baurain J-F. Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients. J Clin Oncol. 2014;32(abstract):3060.
   Google Scholar
• Piulats Rodriguez JM, Ochoa de Olza M, Codes M, Lopez-Martin JA, Berrocal A, Garcia M, Gurpide A, Homet B, Martin-Algarra S. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial. J Clin Oncol. 2014;32:9033. abstract.
   Google Scholar
• Zimmer L, Eigentler TK, Vaubel J-M, Mohr P, Jradi Z, Kiecker F, Utikal J, Berking C, Kampgen E, Hauschild A, et al. Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups. J Clin Oncol. 2014; 32(5s): abstract903
   Google Scholar
• Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer. 2014;50:121–127.
   PubMed Web of Science ®Google Scholar
• Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013;18:726–732.
   PubMed Web of Science ®Google Scholar
• Kottschade LA, McWilliams RR, Markovic S, Block MS, Bisneto JV, Pham AQ, Dronca RS. The use of pembrolizumab for the treatment of metastatic uveal melanoma. J Clin Oncol. 2015;33:9010. abstract.
   Google Scholar
• Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2014;2:15–18.
   PubMed Web of Science ®Google Scholar
• Gajewski TF. Cancer immunotherapy. Mol Oncol. 2012;6:242–250.
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005–1016.
   PubMed Web of Science ®Google Scholar
• Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039–2047.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133. doi:https://doi.org/10.1056/NEJMoa1302369.
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JPPD-1. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107(9):4275–4280. doi:https://doi.org/10.1073/pnas.0915174107.
   PubMed Web of Science ®Google Scholar
• Selby M, Engelhardt J, Lu L-S, Quigley M, Wang C, Chen B, Korman AJ. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J Clin Oncol. 2013;31(15_suppl):3061. doi:https://doi.org/10.1200/jco.2013.31.15_suppl.3061.
   PubMed Web of Science ®Google Scholar
• Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Atkins MB, Kirkwood JM, et al. 2014. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol. 32(18_suppl):LBA9003–LBA9003. abstractLBA9003 https://doi.org/10.1200/jco.2014.32.18_suppl.lba9003.
   Web of Science ®Google Scholar
• Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, et al. Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity. Clin Cancer Res. 2012 Jul 15;18(14):3834–3845. doi:https://doi.org/10.1158/1078-0432.CCR-12-0715.
   PubMed Web of Science ®Google Scholar
• Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res. 2014;4(2):172–181.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunol Res. 2015;3(5):506–517. doi:https://doi.org/10.1158/2326-6066.CIR-14-0211.
   PubMed Web of Science ®Google Scholar
• Leone RD, Lo Y-C, Powell JD. A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J. 2015;13:265–272. doi:https://doi.org/10.1016/j.csbj.2015.03.008.
   PubMed Web of Science ®Google Scholar